- The PN is collecting data on a 45-year-old client with a history of type 2 diabetes. When reviewing the client's immunization status, the PN should identify the need to reinforce teaching about which vaccine?
Answer: Pneumococcal polysaccharide vaccine (PPSV23)
Adults aged 19–64 years with certain chronic medical conditions, including diabetes mellitus, are at increased risk for pneumococcal disease and should receive the pneumococcal vaccine.
- The LPN/VN is reviewing the vaccination plan for a client receiving high-dose systemic corticosteroids for an autoimmune condition. Which vaccine should the nurse flag as contraindicated and report to the RN for review before administration?
Answer: MMR (measles-mumps-rubella) vaccine.
MMR is a live attenuated vaccine and is contraindicated in immunocompromised clients, including those on high-dose systemic corticosteroids (equivalent to 20 mg or more of prednisone daily for 14 or more days). Live vaccines can cause disseminated infection in individuals without adequate immune function. The LPN/VN should flag this and report to the RN before administration. Inactivated influenza vaccine, pneumococcal polysaccharide vaccine, and recombinant hepatitis B vaccine do not contain live organisms and are generally safe to administer to immunocompromised clients, though immune response may be reduced compared to immunocompetent individuals.
- An adult client develops a significant unexpected reaction after receiving an influenza vaccine at the clinic. The LPN/VN knows that which system should be used to report this adverse event?
Answer: Submit a report to the Vaccine Adverse Event Reporting System (VAERS).
The Vaccine Adverse Event Reporting System (VAERS) is the national surveillance system co-managed by the CDC and FDA to which health care providers should report any clinically significant adverse events occurring after vaccination. VAERS reports help detect safety signals and monitor vaccine safety at the population level. Reporting directly to the FDA is not the standard process; VAERS is the designated reporting mechanism. While manufacturers have their own pharmacovigilance systems, provider reporting goes through VAERS. VAERS reporting is encouraged for any significant adverse event, not only those resulting in hospitalization. The National Childhood Vaccine Injury Act requires health care providers to report certain specified adverse events following vaccination.
- The PN is preparing to administer the rotavirus (RV) vaccine to an infant. The PN should prepare to administer this vaccine by which route?
Answer: Oral
The rotavirus vaccine is a live, attenuated virus vaccine that is given as oral drops into the infant's mouth. Knowing the correct route of administration is a fundamental component of safe medication practices.
- The LPN/VN is reinforcing teaching about shingles prevention to a 55-year-old client. Which statement about the recombinant zoster vaccine (Shingrix) is most accurate?
Answer: Shingrix is recommended for adults ages 50 and older as a two-dose series.
Shingrix (recombinant zoster vaccine) is recommended for all immunocompetent adults ages 50 and older as a two-dose series, with the second dose given 2 to 6 months after the first. It is highly effective at preventing shingles and post-herpetic neuralgia. Shingrix is a recombinant subunit vaccine, not a live vaccine, making it safe for most adults including those with a history of chickenpox or prior shingles. In fact, it is recommended precisely because most older adults have had chickenpox (varicella-zoster virus remains dormant and can reactivate). A single dose is not sufficient; two doses are required to achieve the high level of protection demonstrated in clinical trials.
- The PN is reviewing the immunization record of a 4-year-old child. The record shows the child received three doses of DTaP, but the last dose was at 18 months. The child is up to date on all other immunizations. Which action should the PN anticipate?
Answer: Administering the fourth dose of DTaP today.
The DTaP schedule includes five doses total. This child has received three doses with the last at 18 months. At age 4, the child is due for the fourth dose. The fifth dose will be given at school entry (4-6 years old).
- An adult client receiving an annual influenza vaccine asks, "Why do I need this every year when other shots last for many years?" What is the best information for the PN to reinforce?
Answer: The viruses that cause influenza often change each year.
The primary reason for annual influenza vaccination is that influenza viruses constantly change (a process called antigenic drift). The vaccine composition is reviewed each year and updated to match the strains predicted to be most common during the upcoming flu season.
- A client who is 30 weeks pregnant asks the PN if she needs any immunizations before the baby is born. Which statement by the PN provides the most accurate information to reinforce?
Answer: A tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is recommended during each pregnancy.
The Tdap vaccine is recommended for every pregnancy, ideally between 27 and 36 weeks of gestation. This allows the mother to develop antibodies and pass them to the fetus, providing passive protection against pertussis (whooping cough) in early infancy.
- The LPN/VN is assisting at a pediatric immunization clinic. A 12-month-old child is due for MMR, varicella, hepatitis A, and PCV vaccines at today's visit. Which statement best reflects current guidance on administering multiple vaccines at one visit?
Answer: Multiple vaccines can be administered simultaneously at separate injection sites during the same visit.
Current immunization guidelines support administering multiple vaccines simultaneously during the same visit, using separate injection sites for each injectable vaccine. Simultaneous administration is preferred to avoid delaying protection and to minimize the number of clinic visits required. The immune system is capable of responding to multiple antigens at once, and simultaneous administration does not reduce the effectiveness of individual vaccines. The rule that live vaccines must be separated by 4 weeks applies only when they are given on different days, not when given simultaneously on the same day. Limiting visits to two vaccines is not a guideline recommendation and would unnecessarily prolong the time to complete the immunization schedule. MMR and varicella can be given as separate injections or as the combined MMRV; both approaches are acceptable.
- The LPN/VN is reviewing the immunization record of a 14-month-old child at a well-child visit. At which age is the first dose of measles-mumps-rubella (MMR) vaccine recommended according to the standard immunization schedule?
Answer: 12 to 15 months.
The first dose of MMR vaccine is recommended at 12 to 15 months of age, when maternal antibodies have waned sufficiently for the vaccine to produce an effective immune response. A second dose is given at 4 to 6 years. Giving MMR at 6 months is not recommended because residual maternal antibodies can interfere with the immune response to the live attenuated vaccine. The 4 to 6 year age range is the correct timing for the second dose, not the first. MMR is not given at 2 months; it is a live vaccine not given in early infancy when the immune system is less mature and maternal antibodies are still present.
- The practical nurse (PN) is preparing to administer routine immunizations to a 2-month-old infant. The PN should prepare to administer which combination of vaccines?
Answer: DTaP, Haemophilus influenzae type b (Hib), Rotavirus (RV), Pneumococcal (PCV13), IPV
At the 2-month well-child visit, the infant is scheduled to receive the first doses of DTaP, Hib, RV, PCV13, and IPV. These vaccines protect against several serious childhood diseases and follow the CDC immunization schedule for infants.
- The PN is reviewing the immunization records for several children scheduled for appointments today. Which child will require a catch-up immunization schedule?
Answer: A 7-month-old who missed the 6-month appointment and is here for a well-child visit.
A 7-month-old who missed their 6-month visit is behind schedule for the third doses of DTaP, PCV13, Hib, and second dose of rotavirus vaccine. This child will need to follow a catch-up schedule to get back on track with age-appropriate immunizations.
- The parent of a 2-month-old infant calls the clinic the day after receiving routine immunizations. The parent reports the infant's temperature is 99.9°F (37.7°C), the infant is irritable, and there is redness at the injection site. What instruction should the PN reinforce?
Answer: These are common reactions and should resolve within a day or two.
Low-grade fever, mild irritability, and localized redness and swelling are common, expected, and self-limiting side effects following routine immunizations. This response provides appropriate reassurance and reinforces what the parent should expect.
- The PN is preparing to administer an influenza vaccine to an adult client. The client states, "I got the flu shot last year and I still got sick, so I don't think it works." Which response by the PN is most appropriate?
Answer: It's possible you were exposed to the flu before the vaccine became fully effective, or you caught a different virus.
This response provides accurate, non-judgmental information. It takes about two weeks for the body to develop antibodies after vaccination. It's also possible the client had an illness caused by a different respiratory virus. This reinforces teaching and addresses the client's concern.
- A parent asks the LPN/VN how many doses of varicella vaccine their child will receive according to the standard immunization schedule. Which response is most accurate?
Answer: Two doses are recommended - the first at 12 to 15 months and the second at 4 to 6 years.
The standard varicella (chickenpox) vaccination schedule consists of two doses: the first at 12 to 15 months of age and the second at 4 to 6 years. Two doses provide stronger and more durable protection than a single dose and significantly reduce breakthrough chickenpox infections. A single dose without a booster was the earlier recommendation; the two-dose schedule was adopted after studies showed improved protection. The schedule of 2, 4, and 6 months describes the DTaP or other infant vaccines, not varicella. Varicella vaccine is recommended for all children without a contraindication, not only for those without chickenpox history.
- The PN is reviewing the immunization record of a 16-year-old client during a clinic visit. The record shows the client received the first dose of HPV vaccine 13 months ago but no additional doses. What should be the PN's priority action?
Answer: Report to the RN that the client is overdue for the second HPV dose.
The PN should identify that the client is overdue for the second HPV dose and report this finding to the RN. Since the client started the series after age 15, a three-dose schedule is required. The second dose should have been given 1-2 months after the first dose. It is within the PN's scope to identify missed vaccinations and report to the RN for follow-up action.
- The PN is preparing to administer routine immunizations to a 15-month-old child. The child's medical history indicates a diagnosis of a congenital immunodeficiency disorder. The PN should notify the RN and question the administration of which vaccine?
Answer: Measles, mumps, rubella (MMR)
The MMR vaccine is a live attenuated virus vaccine. Live vaccines are contraindicated in individuals with severe immunodeficiency because they can cause a severe or fatal infection. The PN has a responsibility to recognize and report this potential contraindication.
- The LPN/VN is reviewing the catch-up schedule for a child who started the hepatitis B series late. Which principle correctly describes how the catch-up schedule should be applied?
Answer: All previously administered valid doses are counted, and only the remaining doses are given based on minimum acceptable intervals.
A fundamental principle of catch-up immunization is that valid doses previously administered are always counted and do not need to be repeated, regardless of how late they were given. Only the remaining doses in the series need to be administered, using the minimum acceptable intervals specified in the catch-up schedule. This principle prevents unnecessary vaccine doses and speeds completion of the series. Restarting a series from the beginning is never required due to a lapse in the schedule; interruptions do not invalidate prior doses. Minimum intervals between doses exist to ensure adequate immune response; doses given at intervals shorter than the minimum must be repeated, but this is unrelated to adverse reactions. Catch-up intervals may differ from the standard schedule to expedite protection.
- A parent of a 13-month-old child asks the LPN/VN when the hepatitis A vaccine should be given. Which response is most accurate?
Answer: The first dose is recommended at 12 to 23 months, with a second dose given 6 to 18 months after the first.
The hepatitis A vaccine is routinely recommended for all children beginning at 12 to 23 months of age. It is given as a two-dose series, with the second dose administered 6 to 18 months after the first dose. Hepatitis A vaccination is a standard part of the childhood immunization schedule for all children in the United States, not only those traveling internationally. A single dose does not provide complete long-term protection; both doses of the series are required for full immunity. Waiting until age 5 would leave young children unprotected during a period when they are at risk for outbreaks in childcare settings.
- According to the standard immunization schedule, when should a healthy newborn receive the first dose of hepatitis B vaccine?
Answer: At birth, before hospital discharge.
The first dose of hepatitis B vaccine is recommended at birth, prior to hospital discharge, to prevent perinatal transmission of hepatitis B from mother to newborn. The second dose is given at 1 to 2 months of age and the third dose at 6 to 18 months, completing the primary series. Delaying the first dose to the 2-month or 6-month visit misses the critical window for preventing perinatal transmission in infants born to hepatitis B surface antigen-positive mothers. The 12-month visit is far too late for the initial dose and would leave the newborn unprotected during the highest-risk period.
